Trial Profile
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pegaptanib (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- 18 Nov 2014 New trial record